MX2020009745A - Composiciones farmaceuticas que comprenden fumarato de dimetilo. - Google Patents

Composiciones farmaceuticas que comprenden fumarato de dimetilo.

Info

Publication number
MX2020009745A
MX2020009745A MX2020009745A MX2020009745A MX2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A MX 2020009745 A MX2020009745 A MX 2020009745A
Authority
MX
Mexico
Prior art keywords
dimethyl fumarate
pharmaceutical compositions
starch
compositions
gastro
Prior art date
Application number
MX2020009745A
Other languages
English (en)
Inventor
JIMENEZ María PLANELLS
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009745(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2020009745A publication Critical patent/MX2020009745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones farmacéuticas que comprenden (a) fumarato de dimetilo, (b) un diluyente seleccionado de monosacáridos, disacáridos, almidón y derivados de almidón, sales inorgánicas de calcio y magnesio, alcoholes de azúcares, y mezclas de ellos, (c) celulosa microcristalina y (d) croscarmelosa sódica, donde el fumarato de dimetilo no está recubierto con una cubierta gastrorresistente. Estas composiciones están destinadas al tratamiento de algunas enfermedades inflamatorias o trastornos autoinmunes.
MX2020009745A 2013-12-12 2016-06-01 Composiciones farmaceuticas que comprenden fumarato de dimetilo. MX2020009745A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12

Publications (1)

Publication Number Publication Date
MX2020009745A true MX2020009745A (es) 2020-10-08

Family

ID=49917530

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007105A MX2016007105A (es) 2013-12-12 2014-12-05 Composiciones farmaceuticas que comprenden fumarato de dimetilo.
MX2020009745A MX2020009745A (es) 2013-12-12 2016-06-01 Composiciones farmaceuticas que comprenden fumarato de dimetilo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016007105A MX2016007105A (es) 2013-12-12 2014-12-05 Composiciones farmaceuticas que comprenden fumarato de dimetilo.

Country Status (31)

Country Link
US (2) US20160310457A1 (es)
EP (2) EP3079666B1 (es)
JP (3) JP6581088B2 (es)
KR (2) KR102335289B1 (es)
CN (2) CN114159421B (es)
AR (1) AR098746A1 (es)
AU (2) AU2014363792B2 (es)
BR (1) BR112016012179B1 (es)
CA (2) CA2932054C (es)
CL (1) CL2016001415A1 (es)
CY (1) CY1124336T1 (es)
DK (1) DK3079666T3 (es)
EA (1) EA201600457A1 (es)
ES (1) ES2860551T3 (es)
HK (1) HK1224212A1 (es)
HR (1) HRP20210468T1 (es)
HU (1) HUE054408T2 (es)
IL (2) IL287109B (es)
LT (1) LT3079666T (es)
MX (2) MX2016007105A (es)
MY (1) MY179355A (es)
NZ (2) NZ759411A (es)
PH (2) PH12016501043A1 (es)
PL (1) PL3079666T3 (es)
PT (1) PT3079666T (es)
RS (1) RS61658B1 (es)
SG (3) SG10201913080VA (es)
SI (1) SI3079666T1 (es)
TW (2) TWI704915B (es)
UA (2) UA120428C2 (es)
WO (1) WO2015086467A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
WO2016194004A1 (en) * 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
CN108472260B (zh) 2015-12-31 2021-08-10 波尔法玛制药工厂股份公司 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法
EP3407873A1 (en) * 2016-01-28 2018-12-05 Zaklady Farmaceutyczne Polpharma SA Process for preparation of a granulate comprising dimethyl fumarate
JP2019510743A (ja) * 2016-02-12 2019-04-18 ウニヴェルズィテート チューリッヒ 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート（ｄｍｆ）
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
CN110636838A (zh) * 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
KR102197465B1 (ko) * 2019-05-31 2020-12-31 주식회사 큐라클 디메틸푸마르산염을 함유한 장용성 정제
US20230055674A1 (en) * 2019-11-07 2023-02-23 Asahi Kasei Kabushiki Kaisha Cellulose composition and tablet
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US20140099364A2 (en) * 2004-10-08 2014-04-10 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
PL1877059T3 (pl) * 2005-04-28 2010-07-30 Wyeth Llc Mikroniozowany tanaproget i zawierające go kompozycje
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
JP2012514623A (ja) 2009-01-09 2012-06-28 フォーワード・ファルマ・アクティーゼルスカブ １またはそれ以上のフマル酸エステルを含む医薬組成物
EP3466420A1 (en) * 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
WO2012164060A1 (en) * 2011-06-03 2012-12-06 F. Hoffmann-La Roche Ag Methods of treating mesothelioma with a pi3k inhibitor compound
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
CN114146080A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物

Also Published As

Publication number Publication date
EP3079666A1 (en) 2016-10-19
SG10201913080VA (en) 2020-03-30
CY1124336T1 (el) 2022-07-22
CA2932054C (en) 2022-09-20
UA123880C2 (uk) 2021-06-16
RS61658B1 (sr) 2021-04-29
MX2016007105A (es) 2016-08-11
JP2016540003A (ja) 2016-12-22
TWI704915B (zh) 2020-09-21
ES2860551T3 (es) 2021-10-05
NZ759411A (en) 2020-06-26
TW202011953A (zh) 2020-04-01
PH12019502610A1 (en) 2021-02-22
US20160310457A1 (en) 2016-10-27
CA2932054A1 (en) 2015-06-18
AU2019268075B2 (en) 2020-12-17
JP2021130689A (ja) 2021-09-09
KR102335289B1 (ko) 2021-12-06
KR20210150587A (ko) 2021-12-10
IL287109A (en) 2021-12-01
AU2019268075A1 (en) 2019-12-12
CN114159421A (zh) 2022-03-11
HRP20210468T1 (hr) 2021-05-14
HUE054408T2 (hu) 2021-09-28
JP6581088B2 (ja) 2019-09-25
IL287109B (en) 2022-08-01
PL3079666T3 (pl) 2021-09-06
AU2014363792B2 (en) 2019-11-14
AR098746A1 (es) 2016-06-08
BR112016012179A2 (es) 2017-08-08
TWI687218B (zh) 2020-03-11
WO2015086467A1 (en) 2015-06-18
PH12016501043B1 (en) 2016-07-04
EP3079666B1 (en) 2021-02-03
CL2016001415A1 (es) 2017-01-20
HK1224212A1 (zh) 2017-08-18
IL245685A0 (en) 2016-06-30
AU2014363792A1 (en) 2016-06-09
JP2019218385A (ja) 2019-12-26
MY179355A (en) 2020-11-05
PH12016501043A1 (en) 2016-07-04
BR112016012179B1 (pt) 2023-04-18
UA120428C2 (uk) 2019-12-10
KR102353201B1 (ko) 2022-01-18
NZ720287A (en) 2020-05-29
EA201600457A1 (ru) 2016-11-30
PT3079666T (pt) 2021-02-18
SG10201913076PA (en) 2020-02-27
JP6945603B2 (ja) 2021-10-06
TW201605435A (zh) 2016-02-16
CN105813634A (zh) 2016-07-27
LT3079666T (lt) 2021-03-25
IL245685B (en) 2021-10-31
US20210330628A1 (en) 2021-10-28
SG10201802815UA (en) 2018-05-30
EP3656379A1 (en) 2020-05-27
CN114159421B (zh) 2023-08-25
KR20160089397A (ko) 2016-07-27
SI3079666T1 (sl) 2021-04-30
DK3079666T3 (da) 2021-03-22
CA3135273A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
PH12019502610A1 (en) Pharmaceutical compositions comprising dimenthyl fumarate
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3230850A4 (en) Multi-core processor having cache consistency
GB2547397A (en) Configuration based cache coherency protocol selection
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
EA201790785A1 (ru) Производные тетрагидроизохинолина
PT3390390T (pt) Derivados de bipirazolilo úteis para o tratamento de doenças autoimunes
EP3204009A4 (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases
BR112017001758A2 (pt) álcoois polivinílicos diretamente compressíveis
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
HK1225385A1 (zh) 用於治療呼吸病的雜芳基衍生物
EP3113770A4 (en) Orally disintegrating tablet of nabilone comprising mannitol-based granules
EP3406184A4 (en) PROCESSOR FOR ENDOSCOPE
EP3033053A4 (en) Bioresorbable scaffold for treatment of bifurcation lesion
EP3700333A4 (en) ENGINEERING OF NOVEL ENTEROID MODELS TO UNDERSTAND HUMAN ENTERIC DISEASE
EP3024326A4 (en) Novel process for the preparation of levothyroxine sodium
EP3536382A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY SKIN DISEASES
PH12015502703A1 (en) Pharmaceutical compositions
EP3704035A4 (en) TEMPERATURE CONTROL HOUSING FOR MEDICINAL PRODUCTS
IL256812A (en) Heteroaryl carbonitriles for the treatment of disease
IL249374B (en) Pharmaceutical dosage forms containing microcrystalline cellulose
EP3189847A4 (en) Therapeutic or prophylactic agent for itching skin diseases
AU2018904527A0 (en) Low latency inter-processor signalling
SI3413894T1 (sl) Uporaba inhibitorjev aktivnosti ali funkcije PI3K za zdravljenje primarnega sjoegrenovega sindroma
EP3305325A4 (en) ACTIVE AGENT FOR THE THERAPY OF MENTAL ILLNESSES WITH IL-6 INHIBITOR AS AN ACTIVE AGENT